Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

v3.19.2
Accrued Expenses
6 Months Ended
Jun. 30, 2019
Payables and Accruals [Abstract]  
Accrued Expenses
7. ACCRUED EXPENSES

 

Accrued expenses consisted of the following:

 

    June 30, 2019     December 31, 2018  
             
Accrued clinical operations and trials costs   $ 11,935,501     $ 4,914,881  
Accrued product development costs     4,073,377       2,222,093  
Accrued compensation     2,100,531       2,253,621  
Accrued other     947,209       460,596  
Total   $ 19,056,618     $ 9,851,191